Full-Time

Principal Scientist

Computational Biology, Islet Biology

Confirmed live in the last 24 hours

Sana Biotechnology

Sana Biotechnology

201-500 employees

Develops engineered cell therapies for diseases

Biotechnology
Healthcare

Compensation Overview

$175k - $205kAnnually

Senior, Expert

Cambridge, MA, USA

Category
Computational Biology
Genomics
Biology & Biotech
Required Skills
Python
R
Linux/Unix
Requirements
  • Ph.D. in computational biology, genetics, bioinformatics, statistics, or related discipline with 5+ years of industry or relevant academic experience, or M.Sc. with 10+ years or equivalent combination of education/work experience
  • Domain experience in stem cell differentiation and engraftment experiments, especially islet beta cells or other endocrine cell lineages
  • Knowledge of mammalian cell differentiation and methods to assess purity and stability of iPSC generated cell lines
  • Proficiency in Python and R, Unix/Linux, and HPC systems; familiarity with testing frameworks for assuring code correctness
  • Strong scientific background including an understanding of molecular biology, cell biology, and genomics resources
Responsibilities
  • Partner with the beta islet group to design studies, answer biological questions and analyze cell differentiation data.
  • Derive insights from transcriptomic and other omics datasets, including scRNA-seq, bulk RNA-seq, and snRNA-seq that enable therapeutic development.
  • Communicate to a broad audience with a range of technical, analytical, and biological expertise and present results at group meetings.
  • Collaborate with Computational Biology and Computational Engineering groups to provide reproducible, tested, and robust analyses.

Sana Biotechnology develops engineered cells aimed at treating and potentially curing various diseases. Their approach focuses on addressing the root causes of diseases by repairing genes within cells or replacing damaged cells. This method allows for the creation of new types of medicines that can enhance patient outcomes. Sana's main clients include healthcare providers, research institutions, and pharmaceutical companies seeking advanced therapeutic solutions. The company invests heavily in research and development to discover and create new treatments, which they monetize through licensing agreements, partnerships, and direct sales. Unlike many competitors, Sana's focus on cellular and genetic medicine positions them uniquely in the biotechnology sector. Their goal is to lead in the development of therapies that improve patient care by targeting diseases at their genetic and cellular origins.

Company Stage

IPO

Total Funding

$798.6M

Headquarters

Seattle, Washington

Founded

2018

Growth & Insights
Headcount

6 month growth

-1%

1 year growth

-8%

2 year growth

-17%
Simplify Jobs

Simplify's Take

What believers are saying

  • FDA Fast Track designation for SC291 boosts potential in autoimmune disease market.
  • New Bothell facility enhances production capacity for engineered cell therapies.
  • $189.75 million PIPE offering strengthens financial position for innovation.

What critics are saying

  • Resignation of key personnel may delay R&D projects and product timelines.
  • Operational challenges at new Bothell facility could impact production scaling.
  • Competitive pressure from other stem cell therapy companies may increase R&D costs.

What makes Sana Biotechnology unique

  • Sana focuses on engineered cells to treat diseases at genetic and cellular levels.
  • The company targets unmet medical needs with innovative cellular and genetic therapies.
  • Sana's hypoimmune CAR T therapies are pioneering in autoimmune disease treatment.

Help us improve and share your feedback! Did you find this helpful?